文献速递头颈部肿瘤放疗中枢神经肿瘤放疗放疗物理与技术

直立位图像引导质子治疗复发头颈与脑肿瘤的前瞻性临床试验

Prospective clinical trial of upright image-guided proton therapy for locally recurrent head and neck and brain malignancies.
PubMed 文献 · Radiother Oncol · 2025-08-11

该研究对20例复发头颈癌(80%)和脑癌(20%)患者进行计划性中期分析,评估无旋转机架图像引导自适应质子治疗(IGAPT)的可行性、安全性和初步疗效。结果显示,与光子IMRT相比,IGAPT显著降低脑干和脊髓等危机器官剂量,3个月随访完全缓解率达64.3%,毒性以1-2级为主。

要点

  • 无旋转机架IGAPT在复发头颈与脑肿瘤中可行、安全且初步疗效良好。
  • IGAPT较光子IMRT显著降低脑干和脊髓剂量。
  • 3个月随访完全缓解率64.3%,3级毒性发生率20%。

核心结论

  • 无旋转机架IGAPT系统对复发头颈和脑肿瘤的首次临床评估证实其可行、安全且疗效有前景。

研究设计与样本

  • 计划性中期分析纳入20例成人复发头颈癌(80%)和脑癌(20%)患者,中位年龄62岁,ECOG体能状态≤2。
  • 患者接受直立位和仰卧位成像与模拟,治疗计划比较直立位质子治疗与常规仰卧位IMRT。
  • 剂量学分析聚焦危机器官保护和靶区覆盖,毒性每3个月采用CTCAE前瞻性评估。

主要发现

  • 无旋转机架质子治疗较光子IMRT显著降低脑干剂量(6 Gy(RBE) vs 19.1 Gy,p<0.001)和脊髓剂量(12.5 Gy(RBE) vs 18.3 Gy,p<0.006)。
  • 3个月随访(n=14)可评估患者中完全缓解率64.3%,部分缓解率21.4%。
  • 毒性以1-2级为主,主要为皮炎(55%)、乏力(45%)和黏膜炎(31.3%);3级毒性4例(20%),无器械相关死亡。

临床怎么用

  • 该无旋转机架IGAPT系统可用于复发头颈和脑肿瘤的质子治疗,剂量学优势明显且短期安全性可接受。
  • 治疗前需进行直立位和仰卧位成像与模拟,以比较质子治疗与IMRT的剂量学差异。
  • 治疗期间应每3个月采用CTCAE前瞻性评估毒性。

局限性

  • 本文为计划性中期分析,样本量有限(20例),3个月随访可评估患者仅14例。
  • 疗效数据为初步结果,随访时间短,长期局部控制和晚期毒性尚未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The advent of commercially available vertical CT systems has renewed interest in gantry-less proton therapy (PT), in which patients are treated in an upright position using a fixed beamline and robotic positioning. This study evaluates the feasibility, safety, and preliminary efficacy of novel gantry-less image-guided adaptive PT (IGAPT) for recurrent head and neck (HN) and brain malignancies. MATERIALS AND METHODS: A planned interim analysis was performed on 20 adult patients with recurrent HN (80 %) and brain (20 %) cancers, median age 62 years, with Eastern Cooperative Oncology Group (ECOG) performance status ≤2. Patients underwent upright and supine imaging and simulation, followed by treatment planning comparing upright PT to conventional supine intensity-modulated radiotherapy (IMRT). Dosimetric analyses focused on organ-at-risk (OAR) sparing and target coverage. Toxicities were assessed prospectively every three months using the Common Terminology Criteria for Adverse Events (CTCAE). RESULTS: Gantry-less PT demonstrated significant dosimetric advantages over photon IMRT, including reduced doses to critical OARs including brainstem (6 Gy(RBE) vs. 19.1 Gy; p < 0.001) and spinal cord (12.5 Gy(RBE) vs. 18.3 Gy; p < 0.006). At 3-month follow-up (n = 14), a complete response was observed in 64.3 % of evaluable patients and a partial response in 21.4 %. Most toxicities were mild-to-moderate (grades 1-2), primarily dermatitis (55 %), fatigue (45 %), and mucositis (31.3 %). Grade 3 toxicities occurred in four patients (20 %). There were no device-related deaths. CONCLUSIONS: This first clinical evaluation of a novel gantry-less IGAPT system confirms its feasibility, safety, and promising efficacy for recurrent HN and brain cancer, with superior dosimetry and high local control rates. Its cost-effective design may improve global access to the IGAPT.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Blumenfeld P, Pryanichnikov A, Hillman Y, et al. Prospective clinical trial of upright image-guided proton therapy for locally recurrent head and neck and brain malignancies. Radiother Oncol. 2025. PMID: 40803484. doi:10.1016/j.radonc.2025.111097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。